EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Hesperetin Attenuates Liver Fibrosis in Mice by Modulating Selected Gut Microbial Populations and SIRT2-Associated Inflammatory Signaling

Anzhao Wu, Lingjie Xin, Yuji Liang, Luyan Sun, Qian Liu, Bin Wang, YaPing Li, Yuehong Cui, Umar Saeed, Bo Yang, Zahra Zahid Piracha

Iranian Journal of Pharmaceutical Research · 17.06.2026 · 25 (1)

DOI: 10.5812/ijpr-170978 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Iranian Journal of Pharmaceutical Research, online erschienen am 17.06.2026. Verfasst von Anzhao Wu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Integrated Traditional Chinese and Western Medicine, Public Health Clinical Center Affiliated to Shandong University, Jinan, China. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Chronic liver injury progressively induces fibrotic remodeling through persistent inflammatory activity and aberrant extracellular matrix accumulation. Growing evidence indicates that this process involves not only intrahepatic signaling but also gut–liver crosstalk and sirtuin-regulated inflammatory pathways. Hesperetin, a citrus-derived flavanone with reported antioxidant and anti-inflammatory properties, has not been adequately evaluated with respect to microbiota-associated changes and SIRT2-associated signaling during fibrotic liver injury.

Objectives

This study investigated whether hesperetin attenuates CCl4-induced liver fibrosis in mice by modulating selected gut microbial populations and suppressing SIRT2-associated inflammatory signaling pathways.

Methods

Male mice were randomly assigned to the vehicle, CCl4, and CCl4 + hesperetin groups (n = 5 per group). Liver fibrosis was induced by intraperitoneal administration of CCl4 twice weekly for six weeks, and hesperetin was administered orally at 100 mg/kg/day. Histological, biochemical, inflammatory, SIRT2-associated, and selected gut microbial endpoints were assessed. The expression levels of α-SMA, TGF-β1, TNF-α, IL-6, and SIRT2 were quantitatively analyzed using quantitative polymerase chain reaction (qPCR), Western blotting, and an enzyme-linked immunosorbent assay (ELISA). Levels of selected gut microflora were measured using targeted qPCR for Firmicutes, Bacteroidetes, Akkermansia, and Escherichia coli.

Results

CCl4 exposure increased collagen deposition, collagen proportionate area (CPA), and serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities, indicating fibrotic remodeling and hepatocellular injury. Hesperetin treatment significantly decreased collagen deposition and CPA and partially normalized ALT and AST activities compared with CCl4 treatment alone. Fibrosis biomarkers, including α-SMA and TGF-β1, and inflammatory cytokines, including TNF-α and IL-6, showed significant decreases in expression at both the mRNA and protein levels. Hesperetin reduced CCl4-associated SIRT2 upregulation and restored acetyl-α-tubulin levels, suggesting attenuation of SIRT2-associated deacetylase activity.

Conclusions

These exploratory findings suggest that hesperetin attenuates CCl4-induced liver fibrosis by reducing collagen accumulation and biochemical liver injury, suppressing inflammatory and fibrogenic signaling, modulating selected gut microbial populations, and regulating SIRT2-associated acetylation signaling.

Schlagwörter

Stichwörter der Autor:innen

ALTASTCCl4Gut MicrobiotaHesperetinInflammationLiver FibrosisSIRT2Sirius Red Staining

Autor:innen und Institutionen

  • Department of Integrated Traditional Chinese and Western Medicine, Public Health Clinical Center Affiliated to Shandong University, Jinan, China.
  • Department of Pharmacotoxicology, School of Pharmacy, Shandong First Medical University, Jinan, China.
  • Second Department of Hepatology, Public Health Clinical Center Affiliated to Shandong University, Jinan, China.
  • School of Nursing, Shandong University of Traditional Chinese Medicine, Jinan, China.
  • Clinical and Biomedical Research Center (CBRC), Foundation University Islamabad (FUI), Islamabad, Pakistan.
  • Korea University College of Health Sciences, Korea University, Seoul, South Korea.

Zitieren

APA

Wu, A., Xin, L., Liang, Y., Sun, L., Liu, Q., Wang, B., Li, Y., Cui, Y., Saeed, U., Yang, B., & Zahid Piracha, Z. (2026). Hesperetin Attenuates Liver Fibrosis in Mice by Modulating Selected Gut Microbial Populations and SIRT2-Associated Inflammatory Signaling. Iranian Journal of Pharmaceutical Research, 25(1). https://doi.org/10.5812/ijpr-170978

Vancouver

Wu A, Xin L, Liang Y, Sun L, Liu Q, Wang B, et al. Hesperetin Attenuates Liver Fibrosis in Mice by Modulating Selected Gut Microbial Populations and SIRT2-Associated Inflammatory Signaling. Iranian Journal of Pharmaceutical Research. 2026;25(1). doi:10.5812/ijpr-170978

BibTeX
@article{Wu2026,
  author = {Wu, Anzhao and Xin, Lingjie and Liang, Yuji and Sun, Luyan and Liu, Qian and Wang, Bin and Li, YaPing and Cui, Yuehong and Saeed, Umar and Yang, Bo and Zahid Piracha, Zahra},
  title = {Hesperetin Attenuates Liver Fibrosis in Mice by Modulating Selected Gut Microbial Populations and SIRT2-Associated Inflammatory Signaling},
  journal = {Iranian Journal of Pharmaceutical Research},
  year = {2026},
  volume = {25},
  number = {1},
  doi = {10.5812/ijpr-170978}
}
Kostenlos starten →